arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ARDELYX, INC.

ARDX
$2.98 ▼ -0.29 (-9.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

ARDELYX, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $718.3M
Dividend Yield —
Revenue Growth 22.1% ↘
Op. Margin -10.1% ↘
ROIC -11.3% ↘
FCF / Share $-0.18 ↗
Trailing P/E —
Price / Book 4.4x
FCF Yield —
Debt / Equity 1.21
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$407.32M
↑ +22.1% —
Net Income Profit after all expenses
$-61.60M
↓ -57.4% —
Operating Margin Operating profit as % of sales
-10.1%
↓ -20.1% 15th
FCF / Share Free cash flow per share
$-0.18
↑ +6.3% —
Long-Term Debt Long-term obligations
$202.83M
↑ +34.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
13
Returns ↑
20
Financial Health ↑
32
Cash Quality ↓
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 57 quarters